Fact CheckerSign in

NCT05017753Completed

Thoracentesis to Alleviate Cardiac Pleural Effusion

Thoracentesis to Alleviate Cardiac Pleural Effusion - an Interventional Trial (TAP-IT)

Source: ClinicalTrials.gov · Last updated 13 Dec 2024

Brief summary (registry, in English)

The present study will examine the comparative effectiveness of two treatment strategies currently used in the treatment of patients with systolic heart failure presenting with pleural effusion. Patients will be randomized to standard medical treatment only or medical treatment and referral to thoracentesis. Study hypothesis: A strategy of referring patients with heart failure-related pleural effusion to thoracentesis increases number of days alive outside of hospital over the following 90 days.

Status (registry)
Completed
Study type
Interventional
Enrollment
135 (actual)
First submitted
12 Aug 2021
Start date
31 Aug 2021
Primary completion date
22 Mar 2024
Lead sponsor
Bispebjerg Hospital
NCT number
NCT05017753

What you commit to

  • Study type: Interventional
  • Participants enrolled: 135
  • From 31 Aug 2021 to the primary completion date, 22 Mar 2024
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Clinically indicated diagnostic thoracentesis (e.g. suspected malignant aetiology)
  • Recent (\<3 months) intrathoracic procedure (including heart or lung surgery, transcatheter aortic valve implantation (TAVI) or thoracentesis)
  • Planned or expected admission \> 10 days for other condition than heart failure

Lab values

  • Suspected pulmonary or pleural infection (pneumonia symptoms with c- reactive protein\>100 mg/L or white blood count\>11)
  • Contraindications to thoracentesis according to local guidelines (such as spontaneously elevated international normalized ratio (INR) or thrombocytopenia), patients on oral anticoagulation may be randomized.
  • Estimated glomerular filtration rate (eGFR) \<15ml/min/1.73m2 or dialysis treatment

Other

  • Severe aortic stenosis
  • Massive pleural effusion (equivalent to \>2/3 of lung on a standing chest x-ray)
  • Substantially affected hemodynamics (systolic blood pressure \< 85mmHg, need of inotropes) or high oxygen demand (\>7L/min)
  • Inability to give informed consent

Who the study is looking for

  • Left ventricular ejection fraction (LVEF) ≤ 45%
  • Non- negligible pleural effusion by x-ray, ultrasound, CT or MRI, suspected to be due to heart failure
  • Age ≥ 18 years

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Hospital Aalborg
Coordinator of this site? Confirm its status
AalborgDenmarkUnknown status
University Hospital Aarhus
Coordinator of this site? Confirm its status
AarhusDenmarkUnknown status
University Hospital Bispebjerg and Frederiksberg
Coordinator of this site? Confirm its status
CopenhagenDenmarkUnknown status
University Hospital, Rigshospitalet
Coordinator of this site? Confirm its status
CopenhagenDenmarkUnknown status
University Hospital Rigshospitalet, Glostrup
Coordinator of this site? Confirm its status
Glostrup MunicipalityDenmarkUnknown status
University Hospital Herlev/Gentofte
Coordinator of this site? Confirm its status
HerlevDenmarkUnknown status
University Hospital Nordsjaelland
Coordinator of this site? Confirm its status
HillerødDenmarkUnknown status
University Hospital Hvidovre
Coordinator of this site? Confirm its status
HvidovreDenmarkUnknown status
University Hospital Odense
Coordinator of this site? Confirm its status
OdenseDenmarkUnknown status
University Hospital Zealand, Roskilde
Coordinator of this site? Confirm its status
RoskildeDenmarkUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.